UK-based biotechnology company Critical Pharmaceuticals is to collaborate with the University of Nottingham for the development of a nano-enabled intranasal formulation of teriparatide.

Funding worth £545,000 has been provided by the Technology Strategy Board and the Engineering and Physical Sciences Research Council to support the project, designed to create a technology-enabled treatment of osteoporosis.

Teriparatide is commonly used to treat osteoporosis but is currently administered through a daily injection.

The collaboration hopes to develop a nasal spray formulation of the drug, enabling patients to easily administer teriparatide themselves and enhance the drug’s overall efficacy.

Critical Pharmaceuticals hopes to use its CriticalSorb nanotechnology, a best in class absorption promoter that is currently being used alongside a nasal formulation of human growth hormone (CP024), currently in phase I clinical development.

Osteoporosis affects an estimated 75 million people across Europe, the US and Japan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.